<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Breast Cancer Research &#187; JAMA</title>
	<atom:link href="http://breastcancerresearch.info/tag/jama/feed" rel="self" type="application/rss+xml" />
	<link>http://breastcancerresearch.info</link>
	<description>Breast Cancer Treatment, Prevention, Screening And Procedures</description>
	<lastBuildDate>Thu, 09 Feb 2012 00:38:56 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>This Week in JAMA [This Week in JAMA]</title>
		<link>http://breastcancerresearch.info/this-week-in-jama-this-week-in-jama.html</link>
		<comments>http://breastcancerresearch.info/this-week-in-jama-this-week-in-jama.html#comments</comments>
		<pubDate>Fri, 30 Jul 2010 00:38:42 +0000</pubDate>
		<dc:creator></dc:creator>
				<category><![CDATA[Breast Cancer Tumor]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[this]]></category>
		<category><![CDATA[week]]></category>

		<guid isPermaLink="false">http://breastcancerresearch.info/this-week-in-jama-this-week-in-jama.html</guid>
		<description><![CDATA[This Week in JAMA [This Week in JAMA] JAMA. 2010;304(4):377. doi:10.1001/jama.2010.1043 In a retrospective cohort study of 227 521 Medicare beneficiaries who initiated treatment with rosiglitazone or pioglitazone from July 2006 to June 2009, Graham and colleagues (SEE ARTICLE) found that compared with pioglitazone, prescription of rosiglitazone was associated with an increased risk of stroke, [...]]]></description>
			<content:encoded><![CDATA[<p><b>This Week in JAMA [This Week in JAMA]</b><br />
JAMA. 2010;304(4):377. doi:10.1001/jama.2010.1043 In a retrospective cohort study of 227 521 Medicare beneficiaries who initiated treatment with rosiglitazone or pioglitazone from July 2006 to June 2009, Graham and colleagues (SEE ARTICLE) found that compared with pioglitazone, prescription of rosiglitazone was associated with an increased risk of stroke, heart failure, and all-cause mortality &#8230;</p>
<p>Read more on <a href="http://jama.ama-assn.org/cgi/content/short/304/4/377?rss=1">Journal of the American Medical Association</a><br/><br/></p>
]]></content:encoded>
			<wfw:commentRss>http://breastcancerresearch.info/this-week-in-jama-this-week-in-jama.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

